Skip to content
Open access

Efficacy and safety of revascularization in patients with chronic limb-threatening ischemia by kidney function.

Aug 2026 · American Heart Journal · Vol 302, pp. 107550 · 0 citations · 30 references
Medicine

TL;DR

Surgical versus endovascular revascularization was consistently associated with fewer days with MALE across CKD strata, however, its association with mortality varied by kidney function, attenuating the overall benefit for the composite endpoint of MALE or death.

Abstract

Background

The optimal revascularization strategy for patients with chronic limb-threatening ischemia (CLTI) with chronic kidney disease (CKD) remains unknown. We evaluated whether the efficacy and safety of surgical versus endovascular revascularization differ by kidney function.

Methods

In this post hoc secondary analysis of BEST-CLI trial (NCT02060630), 1,704 patients with CLTI were stratified by baseline estimated glomerular filtration rate (eGFR, mL/min/1.73 m²): non-CKD (eGFR≥90), mild-moderate CKD (eGFR 45-89), advanced CKD (eGFR<45 or dialysis). The primary outcome was a composite of major adverse limb events (MALE) or death. We estimated the difference in restricted mean time lost (RMTL, in days) adjusted for inverse probability treatment weights.

Results

Surgical revascularization was significantly associated with fewer days with MALE or death in non-CKD (RMTL difference: -127.8 days; 95% CI -176.1, -79.6) and mild-moderate CKD (-63.2 days; 95% CI -104.7, -21.8) but not in advanced CKD (-16.4 days; 95% CI -78.8, 46.0; P interaction = 0.02). This attenuation reflected a diminishing mortality benefit with more severe CKD (P interaction = 0.01), whereas the association with fewer days with MALE remained consistent across CKD strata (P interaction = 0.34). Major adverse cardiovascular events and serious adverse events were more common with more severe CKD but did not differ significantly by treatment.

Conclusions

Surgical versus endovascular revascularization was consistently associated with fewer days with MALE across CKD strata. However, its association with mortality varied by kidney function, attenuating the overall benefit for the composite endpoint of MALE or death. These results support individualized revascularization strategies, but require prospective confirmation. TRIAL REGISTRATION The BEST CLI trial is registered at ClinicalTrials.gov (NCT02060630).

Read PDF

Similar papers

Oct 2026

Association of chronic kidney disease with major cardiovascular outcomes following lower extremity endovascular revascularization.

OBJECTIVE Chronic kidney disease (CKD) amplifies cardiovascular risk, yet its stage-specific influence on perioperative outcomes following endovascular lower extremity revascularization (LER) for peripheral artery disease (PAD) remains poorly characterized. METHODS We conducted a retrospective cohort study using the...

Namra Khan, Hana Shah, P. Rodriguez de la Vega et al. · 0 citations
Open access Sep 2026

Functional capacity improvement and cardiovascular events after lower extremity revascularization

Among patients with severe PAD undergoing LER with very low DASI, failure to improve functional capacity at 6 months post-LER was associated with higher rates of long-term MACLE and mortality, whereas patients making even modest gains in functional capacity post-LER experienced outcomes comparable to those with consist...

S. Heffron, Yu-He Xia, Crystalann Rodriguez et al. · 0 citations
Open access Oct 2026

Safety and Efficacy of Pulsed Field Ablation for Atrial Fibrillation in Patients With Chronic Kidney Disease.

BACKGROUND Atrial fibrillation (AF) and chronic kidney disease (CKD) are prevalent conditions linked by multiple shared risk factors. OBJECTIVE This study aimed to compare periprocedural safety and long-term efficacy outcomes of pulsed field ablation (PFA) for AF in patients with and without CKD. METHODS Consecutiv...

J. Rodriguez-Riascos, A. Somappa, Camilo A. Estrada-Vargas et al. · 0 citations
Open access Oct 2026

Intravenous Thrombolysis for Acute Ischemic Stroke Across Kidney Function.

BACKGROUND The effectiveness and safety of recombinant tissue-plasminogen activator (rt-PA; alteplase) for acute ischemic stroke in patients with low estimated glomerular filtration rate (eGFR) are uncertain. We evaluated whether the risks and benefits of rt-PA versus no rt-PA vary by eGFR category. METHODS We conduc...

S. Bota, Stephanie N. Dixon, Moira K. Kapral et al. · 0 citations
Open access Oct 2026

Coronary bypass outcomes in chronic limb-threatening ischemia are significantly worse than in patients with non-critical lower extremity arterial disease.

PURPOSE Lower extremity arterial disease (LEAD) is a risk factor in patients undergoing coronary artery bypass grafting (CABG); however, the impact of chronic limb-threatening ischemia (CLTI), its most advanced stage, remains unclear. We evaluated early and long-term outcomes of CABG in CLTI. METHOD We retrospectivel...

Kentaro Shirakura, Yuki Setogawa, Ryohei Ushioda et al. · 0 citations
Open access Sep 2026

Influence of Chronic Kidney Disease on Outcomes After Paclitaxel-Coated Balloon Angioplasty for Coronary In-Stent Restenosis.

BACKGROUND Drug-coated balloons (DCB) are superior to conventional balloon angioplasty in coronary in-stent restenosis. The influence of chronic kidney disease (CKD) on outcomes after DCB for in-stent restenosis is not well described. METHODS A post hoc analysis of the AGENT IDE trial was performed to compare the eff...

Behnam N. Tehrani, I. Vavilin, R. Shlofmitz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.